Solaris Asset Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 135.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,535 shares of the biopharmaceutical company’s stock after purchasing an additional 8,925 shares during the quarter. Solaris Asset Management LLC’s holdings in Pfizer were worth $563,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Beach Investment Management LLC. acquired a new stake in Pfizer during the 2nd quarter worth approximately $5,214,000. Grisanti Capital Management LLC increased its position in Pfizer by 3.7% during the 2nd quarter. Grisanti Capital Management LLC now owns 101,155 shares of the biopharmaceutical company’s stock worth $3,397,000 after purchasing an additional 3,640 shares in the last quarter. 440 Investment Group LLC increased its position in Pfizer by 131.7% during the 2nd quarter. 440 Investment Group LLC now owns 34,156 shares of the biopharmaceutical company’s stock worth $1,147,000 after purchasing an additional 19,414 shares in the last quarter. Westchester Capital Management Inc. increased its position in Pfizer by 11.6% during the 2nd quarter. Westchester Capital Management Inc. now owns 200,269 shares of the biopharmaceutical company’s stock worth $6,727,000 after purchasing an additional 20,762 shares in the last quarter. Finally, Convergence Investment Partners LLC increased its position in Pfizer by 2.6% during the 2nd quarter. Convergence Investment Partners LLC now owns 265,176 shares of the biopharmaceutical company’s stock worth $8,907,000 after purchasing an additional 6,761 shares in the last quarter. 71.41% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,464 shares of company stock valued at $6,767,939. Company insiders own 0.06% of the company’s stock.
PFE has been the subject of a number of research analyst reports. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday, December 15th. UBS Group set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target for the company in a report on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $39.40.
Pfizer Inc. (NYSE PFE) opened at $36.75 on Wednesday. The company has a market capitalization of $218,770.00, a P/E ratio of 21.00, a PEG ratio of 2.07 and a beta of 0.91. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 EPS. sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer declared that its Board of Directors has initiated a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.70%. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s dividend payout ratio is 77.71%.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Shares Bought by Solaris Asset Management LLC” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/14/pfizer-inc-pfe-shares-bought-by-solaris-asset-management-llc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.